Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/88671
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Beltrame, J. | - |
dc.contributor.author | Ganz, P. | - |
dc.contributor.editor | Kaski, J. | - |
dc.contributor.editor | Eslick, G. | - |
dc.contributor.editor | Bairey Merz, C. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Chest pain with normal coronary arteries: a multidisciplinary approach, 2013 / Kaski, J., Eslick, G., Bairey Merz, C. (ed./s), vol.9781447148388, Ch.10, pp.101-117 | - |
dc.identifier.isbn | 1447148371 | - |
dc.identifier.isbn | 9781447148371 | - |
dc.identifier.uri | http://hdl.handle.net/2440/88671 | - |
dc.description | Copyright © 2007 Elsevier B.V. All rights reserved. | - |
dc.description.abstract | The coronary slow flow phenomenon (CSFP) is a microvascular coronary disorder, characterised angiographically by delayed contrast opacification of the distal vasculature in the absence of obstructive coronary artery disease. Its prevalence has been reported as 1–3 % of coronary angiograms performed. It often presents initially as an acute coronary syndrome with 8 % of patients having positive cardiac markers for myocardial infarction. Although transient T wave changes are frequently observed during the acute episode, only a third of patients have clinical evidence of inducible myocardial ischaemia. Both structural and functional studies have demonstrated the presence of microvascular coronary dysfunction however the underlying cause remains elusive. Possible pathogenetic mechanisms include a defective endothelial nitric oxide pathway, excessive endothelin mediated vasoconstriction, autonomic dysfunction, platelet dysfunction, metabolic derangements (associated with the metabolic syndrome and hyperhomocystinaemia), and vascular inflammation. The risk of future cardiac events following the initial presentation appears low however many patients continue to experience recurrent chest pain. Further well-controlled therapeutic studies are required to identify effective therapies for this disabling condition. | - |
dc.description.statementofresponsibility | John Beltrame and Peter Ganz | - |
dc.language.iso | en | - |
dc.publisher | Springer London | - |
dc.rights | © Springer-Verlag London 2013 | - |
dc.source.uri | http://dx.doi.org/10.1007/978-1-4471-4838-8_10 | - |
dc.subject | Coronary slow flow phenomenon | - |
dc.subject | Microvascular coronary dysfunction | - |
dc.subject | Slow flow | - |
dc.subject | Syndrome X | - |
dc.subject | Syndrome Y | - |
dc.subject | Microvascular angina | - |
dc.subject | Coronary heart disease | - |
dc.subject | Normal angiogram | - |
dc.subject | Mibefradil | - |
dc.subject | Nebivolol | - |
dc.subject | Trimetazidine | - |
dc.subject | Statins | - |
dc.subject | Dipyridamole | - |
dc.subject | Endothelin | - |
dc.subject | Endothelial dysfunction | - |
dc.subject | Coronary flow reserve | - |
dc.subject | Microvascular disease | - |
dc.title | The coronary slow flow phenomenon | - |
dc.type | Book chapter | - |
dc.identifier.doi | 10.1007/978-1-4471-4838-8_10 | - |
dc.publisher.place | USA | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Beltrame, J. [0000-0002-4294-6510] | - |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.